These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 1486777)

  • 1. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal treatment for bleeding irregularities in Norplant implant users.
    Alvarez-Sanchez F; Brache V; Thevenin F; Cochon L; Faundes A
    Am J Obstet Gynecol; 1996 Mar; 174(3):919-22. PubMed ID: 8633669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.
    Laurikka-Routti M; Haukkamaa M; Heikinheimo O
    Contraception; 1990 Jul; 42(1):111-20. PubMed ID: 2387151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. III-Menstrual patterns. An international comparative trial.
    Sivin I; Mishell DR; Victor A; Diaz S; Alvarez-Sanchez F; Nielsen NC; Akinla O; Pyorala T; Coutinho E; Faundes A; Roy S; Brenner PF; Ahren T; Pavez M; Brache V; Giwa-Osagie OF; Fasan MO; Zausner-Guelman B; Darze E; Gama daSilva JC; Diaz J; Jackanicz TM; Stern J; Nash HA
    Contraception; 1981 Oct; 24(4):377-92. PubMed ID: 6797783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring.
    Robertson DN; Alvarez F; Sivin I; Brache V; Stern J; Leon P; Faundes A
    Contraception; 1981 Oct; 24(4):469-80. PubMed ID: 6797787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of research and development of vaginal contraceptive rings as a fertility control method in the female.
    Roy S; Mishell Dr
    Res Front Fertil Regul; 1983 May; 2(4):1-10. PubMed ID: 12227323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
    Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
    Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.